Long term responders in frontline multiple myeloma-exception vs expectation of the modern era.
作者信息
Baljevic Muhamed, Sborov Douglas W, Kumar Shaji K
机构信息
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Blood Cancer J. 2024 Jul 17;14(1):115. doi: 10.1038/s41408-024-01100-z.
Abstract
摘要
相似文献
1
Long term responders in frontline multiple myeloma-exception vs expectation of the modern era.一线多发性骨髓瘤的长期缓解者——现代的例外与期望
Blood Cancer J. 2024 Jul 17;14(1):115. doi: 10.1038/s41408-024-01100-z.
2
Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study.新型药物时代髓外多发性骨髓瘤的临床结局：一项多中心研究的见解
Hematol Oncol. 2025 Jul;43(4):e70112. doi: 10.1002/hon.70112.
3
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤自体干细胞移植后维持治疗的真实世界疗效
BMC Cancer. 2025 Feb 5;25(1):204. doi: 10.1186/s12885-025-13518-0.
4
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.含卡非佐米的联合方案作为多发性骨髓瘤的一线治疗：13项试验的荟萃分析
Eur J Haematol. 2017 Jun;98(6):601-607. doi: 10.1111/ejh.12877. Epub 2017 Apr 12.
5
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
6
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).采用苯达莫司汀、泼尼松和硼替佐米（BPV）联合治疗新诊断/未治疗的轻链多发性骨髓瘤患者取得成功。
J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22.
7
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.苯达莫司汀、泼尼松和硼替佐米（BPV）预处理后在新诊断多发性骨髓瘤患者中的干细胞动员及自体干细胞移植
J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15.
8
High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience.高效抗逆转录病毒治疗时代HIV阳性患者多发性骨髓瘤的大剂量化疗及自体干细胞移植：骨髓瘤研究与治疗学会的经验
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):171-4. doi: 10.1016/j.clml.2012.12.004. Epub 2013 Jan 10.
9
Characterization of central nervous system multiple myeloma in the era of novel therapies.新型疗法时代中枢神经系统多发性骨髓瘤的特征分析
Leuk Lymphoma. 2016 Jul;57(7):1709-13. doi: 10.3109/10428194.2015.1122786. Epub 2016 Jan 4.
10
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.硼替佐米和来那度胺时代复发性/难治性多发性骨髓瘤的治疗：系统评价和网络荟萃分析。
Ann Hematol. 2021 Mar;100(3):725-734. doi: 10.1007/s00277-021-04404-3. Epub 2021 Jan 11.
引用本文的文献
1
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.基于卡非佐米的四联组合疗法在新诊断多发性骨髓瘤治疗中的当前及未来作用
Hemasphere. 2025 Jul 16;9(7):e70178. doi: 10.1002/hem3.70178. eCollection 2025 Jul.
本文引用的文献
1
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.自体造血干细胞移植后长期缓解的多发性骨髓瘤患者。
Blood Cancer J. 2024 May 17;14(1):82. doi: 10.1038/s41408-024-01062-2.
2
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
3
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.伊沙佐米、卡非佐米、来那度胺和地塞米松治疗高危初诊多发性骨髓瘤。
J Clin Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. Epub 2023 Sep 27.
4
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤患者（GRIFFIN）：一项开放标签、随机、2 期试验的最终分析。
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
5
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗用于新诊断、适合移植的多发性骨髓瘤患者的诱导治疗（GMMG-HD7）：一项开放标签、多中心、随机、主动对照、3 期临床试验的第 1 部分。
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
6
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.三药联合治疗、移植和维持治疗直至骨髓瘤进展。
N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.
7
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
8
The mutagenic impact of melphalan in multiple myeloma.美法仑在多发性骨髓瘤中的致突变作用。
Leukemia. 2021 Aug;35(8):2145-2150. doi: 10.1038/s41375-021-01293-3. Epub 2021 May 19.
9
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.硼替佐米、来那度胺和地塞米松诱导治疗及适应性维持治疗新诊断多发性骨髓瘤的长期随访结果。
J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16.
10
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.硼替佐米、来那度胺和地塞米松作为多发性骨髓瘤自体移植前的诱导治疗。
Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241.
Zotero 插件